1. Search results in the navigational tree (All hits)
All the results are highlighted by color in the navigational tree
(at the left-hand side) and remain so until you click on a not highlighted menu item and
thus return to the usual content navigation.
In addition, you can browse through the search results consecutively by pressing the navigational buttons
(
<
1 of
7
>).
Within the text the search result is highlighted by color.
2. Search results by relevance (Top 5)
Following is a list of the 5 most important hits ranked by relevance.
Hint: In the
Help you will find explanations about using search operators in order to conduct an extended search.
The operating activities of the Merck Group are organized into four divisions. The Merck Serono division develops, manufactures and markets prescription medicines to treat cardiovascular diseases, cancer, neurodegenerative diseases, infertility, and selected metabolic disorders. More than 60% of Merck Serono’s sales are generated with biologics, making the division one of Europe’s leading suppliers of biopharmaceuticals. In the first quarter of 2013, Merck Serono accounted for around 55% of Group sales. The Consumer Health division manufactures and markets over-the-counter pharmaceuticals that primarily address health themes such as mobility, women’s and [...]
[...] In a first step, the allocation of expenses for Group functions of Merck KGaA to the operating divisions was modified in fiscal 2012. In a further step, the corresponding disclosures for the consolidated subsidiaries were adjusted in fiscal 2013. Consequently, expenses for Group functions are no longer allocated to the operating divisions, but rather disclosed fully in the column ”Corporate and Other“ in the Segment Reporting. In order to ensure comparability, the previous year‘s Segment Reporting figures have been adjusted in accordance with the allocation rules for 2013. The notes to the consolidated financial statements of the Merck Group for 2012, [...]
With the publication of the results of fiscal 2012 on March 7, 2013, Merck provided qualitative guidance on the expected sales and results of its divisions and the Group for 2013. For the markets of relevance to the Merck Serono division, Merck sees global growth, which is likely to be fueled mainly by Emerging Markets, whereas developments in Europe will probably continue to be impacted by health care cost-containment measures. The market environment of Consumer Health should see global growth in the mid single-digit range, with Europe also growing at the same rate. Asia and Latin America could see high single-digit growth rates. The markets in which Performance [...]
[...] This increase was due especially to the performance of the Merck Serono and Performance Materials divisions. The proportion of Group sales accounted for by this region thus increased to 35% (Q1 2012: 33%). In North America, sales grew organically by 5.6% to € 516 million (Q1 2012: € 487 million), with Merck Serono and Merck Millipore driving the increase. This region’s share of Group sales remained unchanged at 19%. In Europe, sales totaled € 1,013 million (Q1 2012: € 1,000 million). Organic sales growth amounted to 1.0% and was primarily attributable to the Consumer Health division. Europe’s share of Group sales decreased slightly to 38% (Q1 2012: [...]
Highlights – 1st Quarter 2013 Sales rise by 3.8% to € 2,660 million; solid organic growth of 5.0% stands against a foreign exchange impact of –1.4% Organic sales growth fueled by all four divisions EBITDA pre one-time items up 18.8% to € 801 million thanks to good business performance and progress with the “Fit for 2018” efficiency program as planned Net income soars by 54.1% to € 266 million, earnings per share before one-time items up 27.1% to € 2.11 Free cash flow increases by 4.5% to € 439 million despite cash outflow of around € 100 million for efficiency measures and a € 195 million increase in working capital Guidance for FY 2013: [...]
